Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2022-10-10 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2022
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return regarding movements in securities, specifically focusing on share capital, issued shares, share options, and confirmations related to securities issued by the issuer. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content includes detailed tables of share capital movements, share options exercised, and confirmations by a director. There is no indication that this is an annual or quarterly financial report, audit report, earnings release, or any other type of report. Instead, it is a regulatory filing reporting share capital and share issuance movements for a specific month (September 2022). This type of document fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit into other specific categories.
2022-10-10 English
GRANT OF SHARE OPTIONS
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the grant of share options under the company's 2022 Equity Incentive Plan. It details the number of options granted, exercise price, vesting period, and other terms related to the share options. It is made pursuant to a listing rule and includes definitions and disclosures typical of a regulatory announcement. There is no indication that this is a full report, financial statement, or management discussion. It is not a report of director dealings in shares (which would be insider trades), but rather a company announcement about share options granted to employees. This fits the category of Share Issue/Capital Change (SHA), as it relates to new share options granted and potential future share issuance upon exercise. The document length is about 5474 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is SHA with high confidence.
2022-10-05 English
2022 INTERIM REPORT
Interim / Quarterly Report Classification · 100% confidence The document is titled as an "interim report" and contains detailed sections such as Management Discussion and Analysis, unaudited interim condensed consolidated financial statements (balance sheets, statements of operations, comprehensive loss, shareholders' equity, cash flows), and notes to the financial statements. It includes forward-looking statements, recent product developments, and financial performance commentary. The presence of unaudited interim condensed consolidated financial statements and substantive financial data indicates this is a comprehensive financial report for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). The document length (15,000 characters) and detailed financial content confirm it is not merely an announcement or certification but the actual report itself.
2022-09-30 English
OVERSEAS REGULATORY ANNOUNCEMENT BUSINESS UPDATE
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing with the U.S. Securities and Exchange Commission, dated September 27, 2022, reporting the entry into a material definitive agreement between Zai Lab Limited and Seagen Inc. The content details a collaboration and license agreement for the development and commercialization of a pharmaceutical product, including payment terms, milestones, and royalties. The document includes regulatory references, specific dates, and detailed contractual terms. It is not a full financial report, earnings release, or management discussion, but a current report on a material event. Therefore, it fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement of a material contract and does not fall under other more specific categories like M&A or Capital Update.
2022-09-27 English
GRANT OF SHARE OPTIONS
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the grant of share options under the company's 2022 Equity Incentive Plan. It details the number of options granted, exercise price, vesting period, and other terms related to the share options. There is no financial performance data, no discussion of quarterly or annual results, no mention of a meeting or voting results, and no indication of a report being attached or published. The content focuses on a specific equity incentive plan grant, which is a capital-related update. According to the filing definitions, announcements about share options and equity incentive plans fall under Capital/Financing Update (CAP). The document is about a grant of share options, which is a financing activity, not a report or regulatory filing. Therefore, the correct classification is CAP with high confidence.
2022-09-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2022
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on share capital, issued shares, share options, and other share-related movements for Zai Lab Limited. It includes data on authorized and issued shares, share options exercised, and confirmations related to securities issuance. The document is submitted to the Hong Kong Exchanges and Clearing Limited and references compliance with listing rules. It is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is not a proxy statement, voting results, or a governance report. The content is focused on share capital changes and share issuance details, which aligns with announcements regarding share issues or capital changes. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length and detail confirm it is a substantive report, not just an announcement of a report or a certification.
2022-09-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.